CoChat
Sign Up
Cited by 120

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Tamburini, Jerome, Elie, Caroline, Bardet, Valérie, Chapuis, Nicolas, Park, Sophie, Broët, Philippe, Cornillet-Lefebvre, Pascale, Lioure, Bruno, Ugo, Valérie, Blanchet, Odile, Ifrah, Norbert, Witz, Francis, Dreyfus, François, Mayeux, Patrick, Lacombe, Catherine, Bouscary, Didier·2007·Blood
DOI 10.1182/blood-2006-12-061283
Open this paper in CoChat — free account

Abstract

The phosphoinositide 3-kinase (PI3K/Akt) pathway is activated in acute myelogenous leukemia (AML) and is promising for targeted inhibition. Ninety-two patients with primary AML were analyzed for PI3K/Akt constitutive activation. Fifty percent of the patients presented with constitutive PI3K activation (PI3K +). No difference was observed between PI3K + and PI3K − groups concerning age, sex, white blood cell count, lactate dehydrogenase (LDH) level, bone marrow blast cells, French-American-British (FAB) classification, cytogenetics, RAS or nucleophosmin (NPM) mutations. Slightly more FLT3-ITD was detected in the PI3K − group (P = .048). The complete remission rate was similar between the 2 groups. With a median follow-up of 26 months, we observed for PI3K + and PI3K − patients, respectively, 56% and 33% overall survival (P = .001) and 72% and 41% relapse-free survival (P = .001). Constitutive PI3K/Akt activity is a favorable prognosis factor in AML, even after adjustment for FLT3-ITD, and may confer a particular sensitivity to chemotherapy. A better understanding of the downstream effectors of the PI3K/Akt pathway is needed before targeting in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2006-12-061283

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 15

  1. Xu, 2003, Survival of acute myeloid leukemia cells requires PI3 kinase activation., Blood, 102, 972, 10.1182/blood-2002-11-3429 · DOI · Paper page
  2. Min, 2003, Constitu-tive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable., Leukemia, 17, 995, 10.1038/sj.leu.2402874 · DOI · Paper page
  3. Grandage, 2005, PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways., Leukemia, 19, 586, 10.1038/sj.leu.2403653 · DOI
  4. Bardet, 2006, Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry., Haematologica, 91, 757
  5. Sujobert, 2005, Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia., Blood, 106, 1063, 10.1182/blood-2004-08-3225 · DOI
  6. Billottet, 2006, A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16., Oncogene, 25, 6648, 10.1038/sj.onc.1209670 · DOI
  7. Cornillet-Lefebvre, 2006, Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations., Leukemia, 20, 374, 10.1038/sj.leu.2404054 · DOI
  8. Kornblau, 2006, Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia., Blood, 108, 2358, 10.1182/blood-2006-02-003475 · DOI
  9. Nakao, 1996, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia., Leukemia, 10, 1911
  10. Bezieau, 2001, High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis., Hum Mutat, 18, 212, 10.1002/humu.1177 · DOI
  11. Bardet, 2006, Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype., Leukemia, 20, 1644, 10.1038/sj.leu.2404294 · DOI
  12. Sawyers, 2006, Will kinase inhibitors have a dark side?, N Engl J Med, 355, 313, 10.1056/NEJMcibr062354 · DOI
  13. Yoeli-Lerner, 2005, Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT., Mol Cell, 20, 539, 10.1016/j.molcel.2005.10.033 · DOI
  14. Broet, 2001, A semiparametric approach for the two-sample comparison of survival times with long-term survivors., Biometrics, 57, 844, 10.1111/j.0006-341X.2001.00844.x · DOI
  15. Gray, 1988, A class of K-sample tests for comparing the cumulative incidence of a competing risk., Ann Stat, 16, 1141, 10.1214/aos/1176350951 · DOI

Cited by

Metadata

Authors
Tamburini, J., Elie, C., Bardet, V., Chapuis, N., Park, S., Broët, P., Cornillet-Lefebvre, P., Lioure, B., Ugo, V., Blanchet, O., Ifrah, N., Witz, F., Dreyfus, F., Mayeux, P., Lacombe, C., & Bouscary, D.
Venue
Blood
Publisher
American Society of Hematology
Published
2007-08-01
Volume
110
Issue
3
Pages
1025-1028
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2006-12-061283
Cited by
120
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review